Print

Rexahn Pharmaceuticals, Inc. Issued Japanese Patent for New Anti-cancer Compounds  
4/30/2012 9:25:22 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled “Quinazoline Derivatives and Therapeutic Use Thereof.” This new patent covers Rexahn’s anti-cancer candidate RX-1792 and related compounds, and a composition for treating anti-proliferative and anti-tumor activities.
//-->